 Megan Adams
Concepts (303)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 33 | 2026 | 826 | 7.590 |
Why?
| | Gastroenterology | 11 | 2025 | 190 | 4.360 |
Why?
| | Anesthesia | 6 | 2023 | 258 | 2.900 |
Why?
| | Delivery of Health Care, Integrated | 5 | 2025 | 299 | 2.840 |
Why?
| | Ambulatory Care | 5 | 2025 | 607 | 2.050 |
Why?
| | Endoscopy, Gastrointestinal | 7 | 2023 | 237 | 1.910 |
Why?
| | End Stage Liver Disease | 5 | 2026 | 95 | 1.870 |
Why?
| | Colonoscopy | 9 | 2023 | 260 | 1.860 |
Why?
| | United States Department of Veterans Affairs | 10 | 2025 | 771 | 1.860 |
Why?
| | Liability, Legal | 5 | 2021 | 42 | 1.700 |
Why?
| | Colorectal Neoplasms | 5 | 2023 | 849 | 1.670 |
Why?
| | Living Donors | 12 | 2025 | 281 | 1.640 |
Why?
| | Malpractice | 4 | 2021 | 44 | 1.480 |
Why?
| | Waiting Lists | 6 | 2026 | 263 | 1.420 |
Why?
| | Telemedicine | 4 | 2025 | 957 | 1.400 |
Why?
| | Veterans Health | 4 | 2023 | 189 | 1.300 |
Why?
| | Hepatoblastoma | 3 | 2026 | 52 | 1.180 |
Why?
| | Gastroenterologists | 2 | 2017 | 21 | 1.040 |
Why?
| | Retrospective Studies | 32 | 2026 | 17149 | 1.040 |
Why?
| | Biliary Atresia | 3 | 2025 | 158 | 0.960 |
Why?
| | Outpatients | 3 | 2020 | 447 | 0.950 |
Why?
| | Humans | 88 | 2026 | 144667 | 0.950 |
Why?
| | Kidney Transplantation | 5 | 2026 | 709 | 0.930 |
Why?
| | Delivery of Health Care | 4 | 2025 | 944 | 0.920 |
Why?
| | United States | 26 | 2026 | 16018 | 0.910 |
Why?
| | Liver Neoplasms | 4 | 2026 | 777 | 0.910 |
Why?
| | Tissue and Organ Procurement | 5 | 2026 | 341 | 0.910 |
Why?
| | Practice Guidelines as Topic | 4 | 2018 | 1569 | 0.910 |
Why?
| | Tissue Donors | 4 | 2026 | 413 | 0.900 |
Why?
| | Liver Cirrhosis | 2 | 2024 | 287 | 0.900 |
Why?
| | Videoconferencing | 1 | 2025 | 65 | 0.870 |
Why?
| | Graft Survival | 12 | 2026 | 510 | 0.850 |
Why?
| | Personal Autonomy | 2 | 2025 | 59 | 0.820 |
Why?
| | Donor Selection | 2 | 2021 | 79 | 0.810 |
Why?
| | Health Services Accessibility | 4 | 2024 | 1098 | 0.780 |
Why?
| | Lung Transplantation | 1 | 2026 | 329 | 0.740 |
Why?
| | Reoperation | 1 | 2025 | 624 | 0.730 |
Why?
| | Inflammatory Bowel Diseases | 2 | 2024 | 365 | 0.710 |
Why?
| | Veterans | 4 | 2024 | 1614 | 0.700 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2021 | 23 | 0.690 |
Why?
| | International Classification of Diseases | 1 | 2022 | 147 | 0.690 |
Why?
| | Airway Extubation | 1 | 2022 | 60 | 0.690 |
Why?
| | Endoscopy, Digestive System | 2 | 2020 | 141 | 0.670 |
Why?
| | Gastrointestinal Diseases | 2 | 2024 | 217 | 0.660 |
Why?
| | Artificial Intelligence | 1 | 2025 | 381 | 0.650 |
Why?
| | Early Detection of Cancer | 4 | 2023 | 472 | 0.630 |
Why?
| | Sexism | 1 | 2021 | 69 | 0.630 |
Why?
| | Strikes, Employee | 1 | 2019 | 1 | 0.590 |
Why?
| | Robotic Surgical Procedures | 3 | 2026 | 183 | 0.580 |
Why?
| | Clinical Decision-Making | 2 | 2021 | 360 | 0.580 |
Why?
| | Gastrointestinal Tract | 1 | 2021 | 207 | 0.560 |
Why?
| | Child | 19 | 2026 | 22600 | 0.540 |
Why?
| | Collective Bargaining | 1 | 2017 | 2 | 0.540 |
Why?
| | Capitation Fee | 1 | 2017 | 14 | 0.530 |
Why?
| | Community Health Services | 1 | 2019 | 231 | 0.520 |
Why?
| | Patient Preference | 1 | 2020 | 226 | 0.510 |
Why?
| | Reimbursement, Incentive | 1 | 2017 | 42 | 0.510 |
Why?
| | Risk Management | 2 | 2016 | 83 | 0.510 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2021 | 387 | 0.500 |
Why?
| | Tape Recording | 1 | 2016 | 11 | 0.500 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2017 | 97 | 0.500 |
Why?
| | Drug Overdose | 1 | 2021 | 371 | 0.500 |
Why?
| | Anesthesiologists | 1 | 2017 | 68 | 0.490 |
Why?
| | Nurses | 1 | 2019 | 168 | 0.490 |
Why?
| | Infant | 11 | 2026 | 10023 | 0.470 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 2 | 2015 | 221 | 0.460 |
Why?
| | Databases, Factual | 5 | 2026 | 1494 | 0.460 |
Why?
| | Cystic Fibrosis | 1 | 2026 | 1166 | 0.460 |
Why?
| | Employment | 1 | 2017 | 184 | 0.460 |
Why?
| | Blood Coagulation Disorders | 3 | 2023 | 196 | 0.460 |
Why?
| | Postoperative Complications | 5 | 2026 | 2950 | 0.450 |
Why?
| | Quality of Health Care | 2 | 2017 | 692 | 0.450 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 1 | 2015 | 24 | 0.440 |
Why?
| | Withholding Treatment | 1 | 2015 | 80 | 0.440 |
Why?
| | Choledocholithiasis | 1 | 2015 | 20 | 0.440 |
Why?
| | Male | 32 | 2026 | 72431 | 0.440 |
Why?
| | Organ Preservation | 2 | 2026 | 125 | 0.430 |
Why?
| | Trust | 1 | 2016 | 155 | 0.430 |
Why?
| | Unnecessary Procedures | 1 | 2015 | 54 | 0.430 |
Why?
| | Perfusion | 2 | 2026 | 249 | 0.430 |
Why?
| | Colonic Polyps | 1 | 2015 | 85 | 0.420 |
Why?
| | Disease Management | 1 | 2018 | 650 | 0.420 |
Why?
| | Acute Kidney Injury | 1 | 2022 | 869 | 0.420 |
Why?
| | Treatment Outcome | 15 | 2026 | 11735 | 0.410 |
Why?
| | Female | 33 | 2026 | 78304 | 0.410 |
Why?
| | Medical Errors | 2 | 2021 | 119 | 0.410 |
Why?
| | Hospitalization | 2 | 2024 | 2446 | 0.410 |
Why?
| | Disclosure | 1 | 2014 | 84 | 0.400 |
Why?
| | Endosonography | 1 | 2015 | 160 | 0.390 |
Why?
| | Tissue Plasminogen Activator | 4 | 2023 | 244 | 0.390 |
Why?
| | Diagnostic Errors | 1 | 2014 | 177 | 0.380 |
Why?
| | Middle Aged | 23 | 2026 | 35971 | 0.380 |
Why?
| | Opioid-Related Disorders | 1 | 2021 | 601 | 0.380 |
Why?
| | Patient Participation | 1 | 2016 | 428 | 0.380 |
Why?
| | Physician-Patient Relations | 2 | 2021 | 589 | 0.370 |
Why?
| | Aged | 14 | 2026 | 25955 | 0.360 |
Why?
| | Aspirin | 1 | 2015 | 402 | 0.360 |
Why?
| | Case-Control Studies | 3 | 2024 | 3603 | 0.350 |
Why?
| | Child, Preschool | 8 | 2026 | 11790 | 0.350 |
Why?
| | Esophageal Neoplasms | 2 | 2017 | 346 | 0.340 |
Why?
| | Attitude of Health Personnel | 2 | 2019 | 1180 | 0.340 |
Why?
| | Guideline Adherence | 1 | 2015 | 586 | 0.340 |
Why?
| | Occult Blood | 2 | 2022 | 39 | 0.330 |
Why?
| | Adolescent | 10 | 2026 | 22409 | 0.330 |
Why?
| | Logistic Models | 3 | 2025 | 2114 | 0.320 |
Why?
| | Decision Support Techniques | 1 | 2015 | 461 | 0.320 |
Why?
| | Hypnotics and Sedatives | 2 | 2023 | 216 | 0.310 |
Why?
| | Fellowships and Scholarships | 1 | 2013 | 355 | 0.300 |
Why?
| | Resuscitation | 2 | 2024 | 310 | 0.300 |
Why?
| | Risk Factors | 7 | 2025 | 10796 | 0.290 |
Why?
| | Mass Screening | 3 | 2023 | 1348 | 0.280 |
Why?
| | Physicians | 1 | 2017 | 949 | 0.280 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 3 | 2017 | 338 | 0.280 |
Why?
| | Adult | 17 | 2026 | 40489 | 0.270 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1360 | 0.270 |
Why?
| | Endoscopy | 2 | 2022 | 317 | 0.270 |
Why?
| | Thrombelastography | 4 | 2022 | 190 | 0.260 |
Why?
| | Adenocarcinoma | 1 | 2014 | 923 | 0.260 |
Why?
| | Graft Rejection | 2 | 2020 | 512 | 0.250 |
Why?
| | Fibrinolysis | 3 | 2023 | 164 | 0.240 |
Why?
| | Echinococcosis | 1 | 2026 | 9 | 0.240 |
Why?
| | Neostigmine | 1 | 2026 | 21 | 0.240 |
Why?
| | Hypoventilation | 1 | 2026 | 17 | 0.230 |
Why?
| | Brain Death | 1 | 2026 | 58 | 0.230 |
Why?
| | Computer Security | 1 | 2025 | 25 | 0.230 |
Why?
| | Bilirubin | 1 | 2026 | 99 | 0.230 |
Why?
| | Cholangitis, Sclerosing | 1 | 2026 | 60 | 0.230 |
Why?
| | Neuromuscular Blockade | 1 | 2026 | 51 | 0.220 |
Why?
| | Confidentiality | 1 | 2025 | 80 | 0.220 |
Why?
| | Blood Coagulation | 3 | 2023 | 268 | 0.220 |
Why?
| | Propensity Score | 2 | 2025 | 373 | 0.220 |
Why?
| | Pleural Effusion, Malignant | 1 | 2024 | 12 | 0.210 |
Why?
| | Survival Rate | 3 | 2026 | 2089 | 0.210 |
Why?
| | Integrases | 1 | 2025 | 122 | 0.210 |
Why?
| | Telephone | 1 | 2025 | 176 | 0.210 |
Why?
| | Longitudinal Studies | 2 | 2022 | 2942 | 0.210 |
Why?
| | Hepatectomy | 1 | 2026 | 274 | 0.200 |
Why?
| | Length of Stay | 3 | 2026 | 1339 | 0.200 |
Why?
| | Endoscopes, Gastrointestinal | 1 | 2023 | 13 | 0.200 |
Why?
| | Cardiovascular Diseases | 1 | 2015 | 2172 | 0.190 |
Why?
| | Cell Lineage | 1 | 2025 | 376 | 0.190 |
Why?
| | Safety-net Providers | 1 | 2024 | 128 | 0.190 |
Why?
| | Adenoviridae Infections | 1 | 2023 | 20 | 0.190 |
Why?
| | Liver Failure | 1 | 2023 | 83 | 0.190 |
Why?
| | Registries | 3 | 2021 | 2392 | 0.190 |
Why?
| | Primary Graft Dysfunction | 1 | 2023 | 33 | 0.190 |
Why?
| | Liver Failure, Acute | 1 | 2023 | 67 | 0.180 |
Why?
| | Liver | 4 | 2026 | 1889 | 0.180 |
Why?
| | Young Adult | 5 | 2026 | 14122 | 0.180 |
Why?
| | Portoenterostomy, Hepatic | 1 | 2022 | 43 | 0.180 |
Why?
| | Communication | 3 | 2023 | 972 | 0.180 |
Why?
| | Renal Replacement Therapy | 1 | 2022 | 99 | 0.170 |
Why?
| | Informed Consent | 2 | 2021 | 197 | 0.170 |
Why?
| | Zebrafish Proteins | 1 | 2025 | 314 | 0.170 |
Why?
| | Laparoscopy | 1 | 2026 | 477 | 0.170 |
Why?
| | Transplant Recipients | 2 | 2020 | 180 | 0.170 |
Why?
| | Sarcoma | 1 | 2023 | 203 | 0.170 |
Why?
| | Uncertainty | 1 | 2021 | 145 | 0.170 |
Why?
| | Risk Assessment | 3 | 2022 | 3729 | 0.170 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2024 | 370 | 0.160 |
Why?
| | Policy | 1 | 2022 | 147 | 0.160 |
Why?
| | Multiple Myeloma | 1 | 2024 | 306 | 0.160 |
Why?
| | Reperfusion | 1 | 2020 | 54 | 0.160 |
Why?
| | Zebrafish | 1 | 2025 | 532 | 0.160 |
Why?
| | Health Facilities | 1 | 2021 | 86 | 0.160 |
Why?
| | Short Bowel Syndrome | 1 | 2020 | 27 | 0.160 |
Why?
| | Hemostatic Techniques | 1 | 2020 | 52 | 0.150 |
Why?
| | Infant, Newborn | 5 | 2025 | 6399 | 0.150 |
Why?
| | Preoperative Care | 1 | 2022 | 379 | 0.150 |
Why?
| | Feasibility Studies | 1 | 2024 | 1103 | 0.150 |
Why?
| | Compensation and Redress | 1 | 2019 | 8 | 0.150 |
Why?
| | Blood Component Transfusion | 1 | 2020 | 104 | 0.150 |
Why?
| | Hospitals, Teaching | 1 | 2020 | 119 | 0.150 |
Why?
| | Organizational Objectives | 1 | 2019 | 66 | 0.150 |
Why?
| | Ethics, Medical | 1 | 2020 | 90 | 0.150 |
Why?
| | Body Mass Index | 2 | 2026 | 2419 | 0.150 |
Why?
| | Cause of Death | 1 | 2021 | 464 | 0.150 |
Why?
| | Digestive System Surgical Procedures | 1 | 2020 | 110 | 0.150 |
Why?
| | Immunocompromised Host | 1 | 2020 | 202 | 0.150 |
Why?
| | Surgical Wound Infection | 1 | 2022 | 330 | 0.140 |
Why?
| | Educational Status | 1 | 2021 | 463 | 0.140 |
Why?
| | Referral and Consultation | 1 | 2024 | 852 | 0.140 |
Why?
| | Liver Cirrhosis, Alcoholic | 1 | 2018 | 19 | 0.140 |
Why?
| | Health Care Reform | 1 | 2019 | 107 | 0.140 |
Why?
| | Age Factors | 2 | 2026 | 3329 | 0.140 |
Why?
| | Perioperative Care | 1 | 2020 | 231 | 0.140 |
Why?
| | Cohort Studies | 3 | 2026 | 5957 | 0.140 |
Why?
| | Investments | 1 | 2017 | 6 | 0.130 |
Why?
| | Horses | 1 | 2019 | 203 | 0.130 |
Why?
| | Labor Unions | 1 | 2017 | 7 | 0.130 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2022 | 1742 | 0.130 |
Why?
| | Pneumoperitoneum | 1 | 2017 | 12 | 0.130 |
Why?
| | Klebsiella Infections | 1 | 2017 | 26 | 0.130 |
Why?
| | Cholecystitis | 1 | 2017 | 24 | 0.130 |
Why?
| | Pandemics | 2 | 2023 | 1700 | 0.130 |
Why?
| | Michigan | 2 | 2016 | 137 | 0.130 |
Why?
| | Organ Transplantation | 1 | 2020 | 247 | 0.130 |
Why?
| | Retirement | 1 | 2017 | 35 | 0.130 |
Why?
| | Cholecystectomy | 1 | 2017 | 61 | 0.130 |
Why?
| | Medical Overuse | 1 | 2017 | 30 | 0.130 |
Why?
| | Respiration, Artificial | 1 | 2022 | 710 | 0.130 |
Why?
| | Mesalamine | 1 | 2017 | 9 | 0.130 |
Why?
| | Skin Diseases, Vesiculobullous | 1 | 2017 | 17 | 0.130 |
Why?
| | Pain | 1 | 2022 | 785 | 0.120 |
Why?
| | Scleritis | 1 | 2017 | 28 | 0.120 |
Why?
| | Obesity | 3 | 2024 | 3070 | 0.120 |
Why?
| | Program Evaluation | 2 | 2017 | 941 | 0.120 |
Why?
| | Alcoholism | 1 | 2023 | 813 | 0.120 |
Why?
| | Gastroesophageal Reflux | 2 | 2017 | 236 | 0.120 |
Why?
| | Critical Illness | 1 | 2022 | 888 | 0.120 |
Why?
| | Immunosuppressive Agents | 1 | 2020 | 834 | 0.120 |
Why?
| | Cost of Illness | 1 | 2018 | 322 | 0.110 |
Why?
| | Insurance, Health | 1 | 2018 | 308 | 0.110 |
Why?
| | Operative Time | 2 | 2026 | 181 | 0.110 |
Why?
| | Colitis, Ulcerative | 1 | 2017 | 148 | 0.110 |
Why?
| | Health Services Research | 1 | 2017 | 392 | 0.110 |
Why?
| | Odds Ratio | 1 | 2017 | 1076 | 0.110 |
Why?
| | Parents | 2 | 2020 | 1395 | 0.110 |
Why?
| | Healthcare Disparities | 1 | 2021 | 736 | 0.110 |
Why?
| | Chemoprevention | 1 | 2015 | 91 | 0.110 |
Why?
| | Reproducibility of Results | 1 | 2022 | 3414 | 0.100 |
Why?
| | Kidney Failure, Chronic | 1 | 2020 | 597 | 0.100 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1537 | 0.100 |
Why?
| | Pancreatitis | 1 | 2015 | 145 | 0.100 |
Why?
| | Time Factors | 2 | 2021 | 7140 | 0.100 |
Why?
| | Internal Medicine | 1 | 2016 | 278 | 0.100 |
Why?
| | Patient Safety | 1 | 2016 | 353 | 0.090 |
Why?
| | Medication Adherence | 1 | 2017 | 540 | 0.090 |
Why?
| | Surveys and Questionnaires | 2 | 2023 | 6041 | 0.090 |
Why?
| | Motivation | 1 | 2016 | 601 | 0.090 |
Why?
| | Kidney | 1 | 2019 | 1495 | 0.090 |
Why?
| | Quality Improvement | 2 | 2017 | 1287 | 0.090 |
Why?
| | Breast Neoplasms | 1 | 2024 | 2365 | 0.090 |
Why?
| | Medicare | 1 | 2017 | 899 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2015 | 2019 | 0.080 |
Why?
| | Societies, Medical | 1 | 2015 | 890 | 0.080 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1995 | 0.080 |
Why?
| | Electronic Health Records | 1 | 2017 | 1176 | 0.070 |
Why?
| | Algorithms | 1 | 2015 | 1844 | 0.060 |
Why?
| | Incidence | 2 | 2026 | 2892 | 0.060 |
Why?
| | Anesthesia Recovery Period | 1 | 2026 | 29 | 0.060 |
Why?
| | Delayed Graft Function | 1 | 2026 | 46 | 0.060 |
Why?
| | Conversion to Open Surgery | 1 | 2026 | 22 | 0.060 |
Why?
| | Neuromuscular Nondepolarizing Agents | 1 | 2026 | 32 | 0.060 |
Why?
| | Cholinesterase Inhibitors | 1 | 2026 | 47 | 0.060 |
Why?
| | Internship and Residency | 1 | 2016 | 1262 | 0.060 |
Why?
| | Clinical Competence | 1 | 2013 | 1237 | 0.060 |
Why?
| | Gene Knock-In Techniques | 1 | 2025 | 60 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 2117 | 0.050 |
Why?
| | Animals | 3 | 2025 | 37948 | 0.050 |
Why?
| | Prospective Studies | 3 | 2020 | 7994 | 0.050 |
Why?
| | Pleural Effusion | 1 | 2024 | 59 | 0.050 |
Why?
| | Biomarkers | 1 | 2015 | 4261 | 0.050 |
Why?
| | CRISPR-Cas Systems | 1 | 2025 | 167 | 0.050 |
Why?
| | Choledochostomy | 1 | 2022 | 10 | 0.050 |
Why?
| | Anastomosis, Roux-en-Y | 1 | 2022 | 26 | 0.050 |
Why?
| | Prevalence | 2 | 2021 | 2839 | 0.050 |
Why?
| | Bile Ducts | 1 | 2022 | 67 | 0.050 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2022 | 85 | 0.050 |
Why?
| | Allografts | 1 | 2023 | 150 | 0.040 |
Why?
| | Adenoviridae | 1 | 2023 | 199 | 0.040 |
Why?
| | Death | 1 | 2023 | 131 | 0.040 |
Why?
| | Creatinine | 1 | 2023 | 509 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2026 | 2033 | 0.040 |
Why?
| | Acetaminophen | 1 | 2023 | 265 | 0.040 |
Why?
| | Intraoperative Period | 1 | 2020 | 69 | 0.040 |
Why?
| | Computer Systems | 1 | 2020 | 55 | 0.040 |
Why?
| | Viscosity | 1 | 2020 | 92 | 0.040 |
Why?
| | Liver Function Tests | 1 | 2020 | 105 | 0.040 |
Why?
| | Kidney Function Tests | 1 | 2020 | 156 | 0.040 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2025 | 906 | 0.040 |
Why?
| | Health Expenditures | 1 | 2021 | 194 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 2023 | 1047 | 0.040 |
Why?
| | Markov Chains | 1 | 2020 | 130 | 0.040 |
Why?
| | Remission Induction | 1 | 2020 | 309 | 0.040 |
Why?
| | Postoperative Period | 1 | 2020 | 351 | 0.040 |
Why?
| | Documentation | 1 | 2021 | 198 | 0.040 |
Why?
| | Transplantation, Homologous | 1 | 2020 | 407 | 0.040 |
Why?
| | Health Care Costs | 1 | 2021 | 425 | 0.030 |
Why?
| | Klebsiella pneumoniae | 1 | 2017 | 47 | 0.030 |
Why?
| | Duodenitis | 1 | 2017 | 6 | 0.030 |
Why?
| | Esophageal Fistula | 1 | 2017 | 21 | 0.030 |
Why?
| | Critical Care | 1 | 2023 | 695 | 0.030 |
Why?
| | Sigmoidoscopy | 1 | 2017 | 14 | 0.030 |
Why?
| | Esophagitis | 1 | 2017 | 67 | 0.030 |
Why?
| | Esophageal Stenosis | 1 | 2017 | 60 | 0.030 |
Why?
| | Enema | 1 | 2017 | 46 | 0.030 |
Why?
| | Colectomy | 1 | 2017 | 106 | 0.030 |
Why?
| | Gastritis | 1 | 2017 | 116 | 0.030 |
Why?
| | Sepsis | 1 | 2022 | 643 | 0.030 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2017 | 136 | 0.030 |
Why?
| | Education | 1 | 2016 | 105 | 0.030 |
Why?
| | Rectum | 1 | 2017 | 183 | 0.030 |
Why?
| | Chronic Disease | 1 | 2021 | 1810 | 0.030 |
Why?
| | Diagnostic Tests, Routine | 1 | 2016 | 107 | 0.030 |
Why?
| | Barrett Esophagus | 1 | 2017 | 165 | 0.030 |
Why?
| | Communication Barriers | 1 | 2016 | 130 | 0.030 |
Why?
| | Meta-Analysis as Topic | 1 | 2015 | 170 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2020 | 2922 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2020 | 5414 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 5870 | 0.020 |
Why?
| | Disease Progression | 1 | 2017 | 2847 | 0.020 |
Why?
| | Mice | 1 | 2023 | 18261 | 0.010 |
Why?
|
|
Adams's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|